{"id":35750,"date":"2025-06-20T23:00:59","date_gmt":"2025-06-20T15:00:59","guid":{"rendered":"https:\/\/flcube.com\/?p=35750"},"modified":"2025-06-20T23:01:01","modified_gmt":"2025-06-20T15:01:01","slug":"dizals-phase-iii-trial-completes-enrollment-for-shuwozhe-in-egfr-exon20ins-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35750","title":{"rendered":"Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC"},"content":{"rendered":"\n

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192<\/a>) announced the completion of patient enrollment for its global multicenter Phase III clinical trial “WU-KONG28”. The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).<\/p>\n\n\n\n

Shuwozhe’s Unique Position<\/strong>
Shuwozhe stands as the world\u2019s only oral targeted therapy for EGFR exon20ins NSCLC. Its excellent efficacy and safety have earned it Breakthrough Therapy Designations (BTDs) in both China and the US across all treatment lines.<\/p>\n\n\n\n

Regulatory and Market Milestones<\/strong>
Shuwozhe was approved in China via priority review and included in the National Reimbursement Drug List (NRDL) within its first year. Currently, it is the only NRDL-reimbursed standard treatment for second-\/later-line EGFR exon20ins NSCLC and holds top-tier recommendations in all major Chinese clinical guidelines.<\/p>\n\n\n\n

US FDA Review<\/strong>
A New Drug Application (NDA) for Shuwozhe for the treatment of second-\/later-line EGFR exon20ins NSCLC was accepted for review by the US FDA in January this year with priority review status. The agency is expected to make its decision in early July 2025.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its…<\/p>\n","protected":false},"author":1,"featured_media":35751,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,191,981],"class_list":["post-35750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-dizal-pharmaceutical","tag-sha-688192"],"yoast_head":"\nDizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial "WU-KONG28". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35750\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC\" \/>\n<meta property=\"og:description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial "WU-KONG28". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35750\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-20T15:00:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-20T15:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC\",\"datePublished\":\"2025-06-20T15:00:59+00:00\",\"dateModified\":\"2025-06-20T15:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750\"},\"wordCount\":207,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2001-1.webp\",\"keywords\":[\"Clinical trial results\",\"Dizal Pharmaceutical\",\"SHA: 688192\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35750#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35750\",\"name\":\"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2001-1.webp\",\"datePublished\":\"2025-06-20T15:00:59+00:00\",\"dateModified\":\"2025-06-20T15:01:01+00:00\",\"description\":\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial \\\"WU-KONG28\\\". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35750\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2001-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2001-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35750#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC - Insight, China's Pharmaceutical Industry","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial \"WU-KONG28\". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35750","og_locale":"en_US","og_type":"article","og_title":"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC","og_description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial \"WU-KONG28\". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).","og_url":"https:\/\/flcube.com\/?p=35750","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-20T15:00:59+00:00","article_modified_time":"2025-06-20T15:01:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35750#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35750"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC","datePublished":"2025-06-20T15:00:59+00:00","dateModified":"2025-06-20T15:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35750"},"wordCount":207,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","keywords":["Clinical trial results","Dizal Pharmaceutical","SHA: 688192"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35750#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35750","url":"https:\/\/flcube.com\/?p=35750","name":"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35750#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","datePublished":"2025-06-20T15:00:59+00:00","dateModified":"2025-06-20T15:01:01+00:00","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its global multicenter Phase III clinical trial \"WU-KONG28\". The trial evaluates its proprietary lung cancer targeted therapy Shuwozhe (sunvozertinib) versus platinum-based chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35750#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35750"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35750#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","width":1080,"height":608,"caption":"Dizal's Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35750#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2001-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35750"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35750\/revisions"}],"predecessor-version":[{"id":35752,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35750\/revisions\/35752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35751"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}